Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: A randomized phase I trial

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Combadière, Behazine ^a,b,c   Vogt, Annika ^d   Mahé, Brice ^a,b,c   Costagliola, Dominique ^a,b   Hadam, Sabrina ^d   Bonduelle, Olivia ^a,b,c   Sterry, Wolfram ^d   Staszewski, Shlomo ^e   Schaefer, Hans ^d   van der Werf, Sylvie ^f   Katlama, Christine ^b,c,g   Autran, Brigitte ^a,b,c   Blume Peytavi, Ulrike ^d  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f INSTITUT PASTEUR   (France)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; TETAGRIP; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ERYTHEMA; FLOW CYTOMETRY; HAIR FOLLICLE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; MYALGIA; PAIN; PHASE 1 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SWELLING; VACCINATION;

ADMINISTRATION, CUTANEOUS; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DEMOGRAPHY; FLOW CYTOMETRY; HEALTH; HIV INFECTIONS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRAMUSCULAR; TETANUS TOXOID; VACCINATION; VACCINES, INACTIVATED; YOUNG ADULT;

AVIAN INFLUENZA VIRUS;

EID: 77956293519     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010818     Document Type: Article

References (91)

1. Wharton M, Strikas RA, Harpaz R, Rotz LD, Schwartz B, et al. (2003) Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 52: 1-16.
2. Patterson S, Papagatsias T, Benlahrech A (2009) Use of adenovirus in vaccines for HIV. Handb Exp Pharmacol. pp 275-293.
3. Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, et al. (2009) Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res Hum Retroviruses 25: 103-114.
4. White A (2008) Why vaccines are not the answer - the failure of V520 and the importance of cell-mediated immunity in the fight against HIV. Med Hypotheses 71: 909-913.
5. Doherty PC, Hou S, Tripp RA (1994) CD8+ T-cell memory to viruses. Curr Opin Immunol 6: 545-552.
6. Kaech SM, Wherry EJ, Ahmed R (2002) Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2: 251-262.
7. Robinson HL (2003) T cells versus HIV-1: fighting exhaustion as well as escape. Nat Immunol 4: 12-13.
8. Post J, Ratnarajah S, Lloyd AR (2009) Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci 66: 733-756.
9. Brown LE, Kelso A (2009) Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol Cell Biol.
10. Seder RA, Darrah PA, Roederer M (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247-258.
11. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, et al. (2008) Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710-722.
12. Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, et al. (2003) Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 171: 4893-4897.
13. Boon AC, de Mutsert G, Fouchier RA, Osterhaus AD, Rimmelzwaan GF (2005) Functional profile of human influenza virus-specific cytotoxic T lymphocyte activity is influenced by interleukin-2 concentration and epitope specificity. Clin Exp Immunol 142: 45-52.
14. Boon AC, de Mutsert G, van Baarle D, Smith DJ, Lapedes AS, et al. (2004) Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes. J Immunol 172: 2453-2460.
15. Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, et al. (2005) High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201: 241-248.
16. Lau LL, Jamieson BD, Somasundaram T, Ahmed R (1994) Cytotoxic T-cell memory without antigen. Nature 369: 648-652.
17. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, et al. (2003) Duration of antiviral immunity after smallpox vaccination. Nat Med.
18. Combadiere B, Boissonnas A, Carcelain G, Lefranc E, Samri A, et al. (2004) Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med 199: 1585-1593.
19. Demkowicz WE, Jr., Littaua RA, Wang J, Ennis FA (1996) Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J Virol 70: 2627-2631.
20. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5: 296-306.
21. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245-252.
22. Kupper TS, Fuhlbrigge RC (2004) Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 4: 211-222.
23. Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, et al. (2008) Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 29: 497-510.
24. Combadiere B, Mahe B (2008) Particle-based vaccines for transcutaneous vaccination. Comp Immunol Microbiol Infect Dis 31: 293-315.
25. Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA (2004) Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 113: 998-1007.
26. Berzofsky JA, Ahlers JD, Belyakov IM (2001) Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 1: 209-219.
27. Le Borgne M, Etchart N, Goubier A, Lira SA, Sirard JC, et al. (2006) Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity 24: 191-201.
28. Bos JD, Kapsenberg ML (1993) The skin immune system: progress in cutaneous biology. Immunol Today 14: 75-78.
29. Glenn GM, Rao M, Matyas GR, Alving CR (1998) Skin immunization made possible by cholera toxin. Nature 391: 851.
30. Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, et al. (1998) Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol 161: 3211-3214.
31. Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, et al. (2000) Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 6: 1403-1406.
32. Hammond SA, Walwender D, Alving CR, Glenn GM (2001) Transcutaneous immunization: T cell responses and boosting of existing immunity. Vaccine 19: 2701-2707.
33. Matyas GR, Friedlander AM, Glenn GM, Little S, Yu J, et al. (2004) Needle-free skin patch vaccination method for anthrax. Infect Immun 72: 1181-1183.
34. Glenn GM, Flyer DC, Ellingsworth LR, Frech SA, Frerichs DM, et al. (2007) Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Rev Vaccines 6: 809-819.
35. Frerichs DM, Ellingsworth LR, Frech SA, Flyer DC, Villar CP, et al. (2008) Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch. Vaccine 26: 2782-2787.
36. Vogt A, Combadiere B, Hadam S, Stieler KM, Lademann J, et al. (2006) 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J Invest Dermatol 126: 1316-1322.
37. Vogt A, Mahe B, Costagliola D, Bonduelle O, Hadam S, et al. (2008) Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans. J Immunol 180: 1482-1489.
38. Vogt A, Mandt N, Lademann J, Schaefer H, Blume-Peytavi U (2005) Follicular targeting-a promising tool in selective dermatotherapy. J Investig Dermatol Symp Proc 10: 252-255.
39. Doherty PC, Turner SJ, Webby RG, Thomas PG (2006) Influenza and the challenge for immunology. Nat Immunol 7: 449-455.
40. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, et al. (2009) Preexisting immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 106: 20365-20370.
41. Kohlmeier JE, Woodland DL (2009) Immunity to respiratory viruses. Annu Rev Immunol 27: 61-82.
42. Cerwenka A, Morgan TM, Dutton RW (1999) Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial. J Immunol 163: 5535-5543.
43. Kohlmeier JE, Rumsey LM, Chan MA, Benedict SH (2003) The outcome of T-cell costimulation through intercellular adhesion molecule-1 differs from costimulation through leucocyte function-associated antigen-1. Immunology 108: 152-157.
44. Walker BD, Burton DR (2008) Toward an AIDS vaccine. Science 320: 760-764.
45. Goulder PJ, Watkins DI (2008) Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 8: 619-630.
46. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC (2008) Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 14: 617-621.
47. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, et al. (2009) Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15: 293-299.
48. Mahe B, Vogt A, Liard C, Duffy D, Abadie V, et al. (2008) Nanoparticle-Based Targeting of Vaccine Compounds to Skin Antigen-Presenting Cells By Hair Follicles and their Transport in Mice. J Invest Dermatol.
49. Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, et al. (1999) Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci USA 96: 1036-1041.
50. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, et al. (2007) Differential antigen processing by dendritic cell subsets in vivo. Science 315: 107-111.
51. Stoitzner P, Tripp CH, Douillard P, Saeland S, Romani N (2005) Migratory Langerhans cells in mouse lymph nodes in steady state and inflammation. J Invest Dermatol 125: 116-125.
52. Stoitzner P, Tripp CH, Eberhart A, Price KM, Jung JY, et al. (2006) Langerhans cells cross-present antigen derived from skin. Proc Natl Acad Sci USA 103: 7783-7788.
53. Kissenpfennig A, Malissen B (2006) Langerhans cells-revisiting the paradigm using genetically engineered mice. Trends Immunol 27: 132-139.
54. Matsuo M, Nagata Y, Sato E, Atanackovic D, Valmori D, et al. (2004) IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. Proc Natl Acad Sci USA 101: 14467-14472.
55. Ratzinger G, Baggers J, de Cos MA, Yuan J, Dao T, et al. (2004) Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. J Immunol 173: 2780-2791.
56. Belyakov IM, Ahlers JD, Berzofsky JA (2004) Mucosal AIDS vaccines: current status and future directions. Expert Rev Vaccines 3: S65-73.
57. Otberg N, Richter H, Schaefer H, Blume-Peytavi U, Sterry W, et al. (2004) Variations of hair follicle size and distribution in different body sites. J Invest Dermatol 122: 14-19.
58. Mangelsdorf S, Otberg N, Maibach HI, Sinkgraven R, Sterry W, et al. (2006) Ethnic variation in vellus hair follicle size and distribution. Skin Pharmacol Physiol 19: 159-167.
59. Etchart N, Hennino A, Friede M, Dahel K, Dupouy M, et al. (2007) Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans. Vaccine 25: 6891-6899.
60. Yagi H, Hashizume H, Horibe T, Yoshinari Y, Hata M, et al. (2006) Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. Cancer Res 66: 10136-10144.
61. Doherty PC, Topham DJ, Tripp RA, Cardin RD, Brooks JW, et al. (1997) Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 159: 105-117.
62. Hou S, Hyland L, Ryan KW, Portner A, Doherty PC (1994) Virus-specific CD8+ T-cell memory determined by clonal burst size. Nature 369: 652-654.
63. Haanen JB, Wolkers MC, Kruisbeek AM, Schumacher TN (1999) Selective expansion of cross-reactive CD8(+) memory T cells by viral variants. J Exp Med 190: 1319-1328.
64. Watabe S, Xin KQ, Ihata A, Liu LJ, Honsho A, et al. (2001) Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 19: 4434-4444.
65. Graham MB, Braciale TJ (1997) Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J Exp Med 186: 2063-2068.
66. Epstein SL, Lo CY, Misplon JA, Bennink JR (1998) Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol 160: 322-327.
67. Pala P, Townsend AR, Askonas BA (1986) Viral recognition by influenza A virus cross-reactive cytotoxic T (Tc) cells: the proportion of Tc cells that recognize nucleoprotein varies between individual mice. Eur J Immunol 16: 193-198.
68. Townsend ARM, Rothbard J, Gotch FM, Bahadur G, Wraith D, et al. (1986) The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44: 959-968.
69. Belz GT, Doherty PC (2001) Virus-specific and bystander CD8+ T-cell proliferation in the acute and persistent phases of a gammaherpesvirus infection. J Virol 75: 4435-4438.
70. Belz GT, Xie W, Doherty PC (2001) Diversity of epitope and cytokine profiles for primary and secondary influenza a virus-specific CD8+ T cell responses. J Immunol 166: 4627-4633.
71. Belz GT, Xie W, Altman JD, Doherty PC (2000) A previously unrecognized H-2D(b)-restricted peptide prominent in the primary influenza A virus-specific CD8(+) T-cell response is much less apparent following secondary challenge. J Virol 74: 3486-3493.
72. Tamura M, Kuwano K, Kurane I, Ennis FA (1998) Definition of amino acid residues on the epitope responsible for recognition by influenza A virus H1-specific, H2-specific, and H1- and H2-cross-reactive murine cytotoxic T-lymphocyte clones. J Virol 72: 9404-9406.
73. Kuwano K, Tamura M, Ennis FA (1990) Cross-reactive protection against influenza A virus infections by an NS1-specific CTL clone. Virology 178: 174-179.
74. Kuwano K, Scott M, Young JF, Ennis FA (1989) Active immunization against virus infections due to antigenic drift by induction of crossreactive cytotoxic T lymphocytes. J Exp Med 169: 1361-1371.
75. Kuwano K, Braciale TJ, Ennis FA (1989) Cytotoxic T lymphocytes recognize a cross-reactive epitope on the transmembrane region of influenza H1 and H2 hemagglutinins. Viral Immunol 2: 163-173.
76. Kuwano K, Scott M, Young JF, Ennis FA (1988) HA2 subunit of influenza A H1 and H2 subtype viruses induces a protective cross-reactive cytotoxic T lymphocyte response. J Immunol 140: 1264-1268.
77. Murasko DM, Bernstein ED, Gardner EM, Gross P, Munk G, et al. (2002) Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 37: 427-439.
78. Bernstein E, Kaye D, Abrutyn E, Gross P, Dorfman M, et al. (1999) Immune response to influenza vaccination in a large healthy elderly population. Vaccine 17: 82-94.
79. Makedonas G, Betts MR (2006) Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection. Springer Semin Immunopathol 28: 209-219.
80. Harari A, Dutoit V, Cellerai C, Bart PA, Du Pasquier RA, et al. (2006) Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev 211: 236-254.
81. Fan H, Lin Q, Morrissey GR, Khavari PA (1999) Immunization via hair follicles by topical application of naked DNA to normal skin. Nat Biotechnol 17: 870-872.
82. Lademann J, Otberg N, Jacobi U, Hoffman RM, Blume-Peytavi U (2005) Follicular penetration and targeting. J Investig Dermatol Symp Proc 10: 301-303.
83. Lademann J, Richter H, Schaefer UF, Blume-Peytavi U, Teichmann A, et al. (2006) Hair follicles - a long-term reservoir for drug delivery. Skin Pharmacol Physiol 19: 232-236.
84. Naito S, Maeyama J, Mizukami T, Takahashi M, Hamaguchi I, et al. (2007) Transcutaneous immunization by merely prolonging the duration of antigen presence on the skin of mice induces a potent antigen-specific antibody response even in the absence of an adjuvant. Vaccine 25: 8762-8770.
85. Glenn GM, Kenney RT (2006) Mass vaccination: solutions in the skin. Curr Top Microbiol Immunol 304: 247-268.
86. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM (2004) Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351: 2295-2301.
87. Halperin SA, Smith B, Clarke K, Treanor J, Mabrouk T, et al. (2005) Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults. Hum Vaccin 1: 37-42.
88. Draenert R, Altfeld M, Brander C, Basgoz N, Corcoran C, et al. (2003) Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods 275: 19-29.
89. Beavis AJ, Kalejta RF (2001) Simultaneous analysis of the cyan, green, and yellow fluorescent proteins. Curr Protoc Cytom Chapter 1: Unit 1 16.
90. Appay V, Rowland-Jones SL (2002) The assessment of antigen-specific CD8+ T cells through the combination of MHC class I tetramer and intracellular staining. J Immunol Methods 268: 9-19.
91. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, et al. (2000) HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 192: 63-75.